XML 63 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1

Segment Information (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Reportable Segment Information

Reportable segment information is as follows:

			December 31,
(DOLLARS IN MILLIONS)			2021						2020						2019
Net sales
Nourish			$	6,264					$	2,886					$	2,978
Health & Biosciences			2,329						134						129
Scent			2,254						2,064						2,033
Pharma Solutions			809						—						—
Consolidated			$	11,656					$	5,084					$	5,140

			December 31,
(DOLLARS IN MILLIONS)			2021						2020
Segment assets
Nourish			$	17,449					$	8,534
Health & Biosciences			14,774						1,375
Scent			4,078						3,646
Pharma Solutions			3,357						—
Consolidated			$	39,658					$	13,555

			December 31,
(DOLLARS IN MILLIONS)			2021						2020						2019
Segment Adjusted Operating EBITDA:
Nourish			$	1,172					$	599					$	658
Health & Biosciences			625						40						33
Scent			463						416						425
Pharma Solutions			165						—						—
Total			2,425						1,055						1,116
Depreciation & Amortization			(1,156)						(325)						(323)
Interest Expense			(289)						(132)						(138)
Other income, net			58						7						30
Operational Improvement Initiatives (a)			—						—						(2)
Frutarom Integration Related Costs (b)			(4)						(10)						(55)
Restructuring and Other Charges			(41)						(17)						(30)
Gains (Losses) on Sale of Assets			1						(4)						(3)
Shareholder Activism Related Costs (c)			(7)						—						—
Business Divestiture Costs (d)			(42)						—						—
Employee Separation Costs (e)			(29)						(3)						—
Frutarom Acquisition Related Costs (f)			(2)						(1)						(6)
Compliance Review & Legal Defense Costs (g)			—						(3)						(11)
N&B Inventory Step-Up Costs			(368)						—						—
N&B Transaction Related Costs (h)			(91)						(29)						(21)
N&B Integration Related Costs (i)			(101)						(97)						—
Income Before Taxes			$	354					$	441					$	557

(a)			Represents accelerated depreciation related to plant relocations in India and China.
(b)			Represents costs related to the integration of the Frutarom acquisition. For 2021, costs primarily related to performance stock awards. For 2020, costs primarily related to advisory services, retention bonuses and performance stock awards. For 2019, costs primarily related to advisory services.
(c)			Represents shareholder activist related costs, primarily professional fees.
(d)			Represents costs related to the Company's sales and planned sales of businesses, primarily legal and professional fees.
(e)			Represents costs related to severance, including accelerated stock compensation expense, for certain employees and executives who have been separated or will separate from the Company.
(f)			Represents transaction-related costs and expenses related to the acquisition of Frutarom. For 2021, amount primarily includes earn-out payments, net of adjustments. For 2020, amount primarily includes earn-out payments, net of adjustments, amortization for inventory "step-up" costs and transaction costs primarily related to the 2019 Acquisition Activity. For 2019, amount primarily includes amortization for inventory "step-up" costs and transaction costs.
(g)			Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits.
(h)			Represents transaction costs and expenses related to the transaction with N&B, primarily legal and professional fees.
(i)			Represents costs primarily related to advisory services for the integration of the transaction with N&B, primarily consulting fees.

Segment capital expenditures and depreciation and amortization consisted as follows:

			Capital Expenditures																		Depreciation and Amortization
(DOLLARS IN MILLIONS)			2021						2020						2019						2021						2020						2019
Nourish			$	183					$	98					$	126					$	594					$	211					$	210
Health & Biosciences			139						7						8						353						36						34
Scent			41						87						102						84						78						79
Pharma Solutions			30						—						—						125						—						—
Consolidated			$	393					$	192					$	236					$	1,156					$	325					$	323

Long-lived Assets by Geographic Areas

Long-lived assets, net, by country, consisted as follows:

			December 31,
(DOLLARS IN MILLIONS)			2021						2020
United States			$	2,041					$	572
China			259						172
Denmark			251						—
Finland			196						—
France			188						28
Germany			156						7
Other			1,277						679
Consolidated			$	4,368					$	1,458

Net Sales by Geographic Area

Net sales are attributed to individual regions based upon the destination of product delivery and are as follows:

			Net Sales by Geographic Area
(DOLLARS IN MILLIONS)			2021						2020						2019
Europe, Africa and Middle East			$	4,093					$	1,987					$	2,082
Greater Asia			2,728						1,162						1,163
North America			3,499						1,228						1,170
Latin America			1,336						707						725
Consolidated			$	11,656					$	5,084					$	5,140

			Net Sales by Geographic Area
(DOLLARS IN MILLIONS)			2021						2020						2019
Net sales related to the U.S.			$	3,211					$	1,093					$	1,053
Net sales attributed to all foreign countries			8,445						3,991						4,087

X

- Definition

Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

+ Details

Name:	us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration